Action potential prolongation is a common finding in human heart failure and in animal models of cardiac hypertrophy. The mechanism of action potential prolongation involves altered expression of a variety of depolarising and hyperpolarising currents in the myocardium. In particular, decreased density of the transient outward potassium current seems to play a prominent role, regardless of species, precipitating factors or the severity of hypertrophy. The decreased density of the transient outward current appears to be caused by reduced transcription of Kv4.2 and Kv4.3 and may be caused in part by an inhibitory effect of a-adrenoceptor stimulation. During the early stage of the disease process, action potential prolongation may increase the amplitude of the intracellular calcium transient, causing positive inotropy. We argue therefore, that action prolongation may be a compensatory response which may acutely support the compromised cardiac output. In severe hypertrophy and end-stage heart failure however, despite continued action potential prolongation, the amplitude of the calcium transient becomes severely reduced. The mechanism underlying this event appears to involve reduced expression of calcium handling proteins, and these late events may herald the onset of failure. At present the events leading to the late changes in calcium handling are poorly understood. However, chronic activation of compensatory mechanisms including action potential prolongation may trigger these late events. In the present article we outline a hypothesis which describes a potential role for action potential prolongation, and the associated elevation in the levels of intracellular calcium, in maladaptive gene expression and the progression toward cardiac failure. q 1998 Elsevier Science B.V.
Introduction
Cardiac failure has numerous etiologies including myocardial infarction, hypertension, myocarditis and car-Ž diomyopathy resulting from genetic abnormalities such as mutations in the b-myosin heavy chain, dystrophin or . mitochondrial t-RNA genes . About 50% of heart failure cases result from coronary artery disease with the remainder arising from non-ischaemic, and often unknown, etiologies.
Myocyte loss or systolic dysfunction is typically associated with activation of the sympathetic nervous system, ) Ž . Ž . Corresponding author. Tel. q1-416 340 4083; Fax q1-416 340 4596; E-mail: p.backx@utoronto.ca inducing positive inotropy and chronotropy, which acutely support the compromised cardiac output. Myocyte adaptation including concentric myocyte hypertrophy and altered gene expression, further attempt to reverse diminished w x cardiac function 1-4 . However, in spite of the compensatory response, cardiac function may continue to decline.
Chronic myocyte adaptation appears to be associated with diminished systolic and diastolic function and myocyte loss, perhaps as a result of maladaptive hypertrophy and ongoing apoptosis, and these factors have been postulated to be involved in the progressive decline in pump function w x and the onset of heart failure 5-9 . In addition, myocyte Time for primary review 38 days.
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at Pennsylvania State University on February 21, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from ( )adaptation seems to predispose the heart toward lethal Ž . ventricular arrhythmia, a leading cause of death 50-80% in patients with dilated or hypertrophic heart disease. Thus, whilst myocyte hypertrophy and remodelling may compensate for the original changes in load, these adaptations may ultimately contribute to arrhythmogenesis, mechanical dysfunction and progressive cardiac dysfunction.
The mechanism by which myocyte adaptation leads ultimately to failure is unclear. However, an understanding of the molecular events that occur following an insult to pump function may shed some light on this process. One of the most commonly reported aspects of the remodelling process is action potential prolongation. In the present article we review the data on action potential duration in hypertrophy and failure and it's probable causes. We conclude that action potential prolongation represents an early compensatory event. A second common finding in human and animal models of heart failure is altered calcium handling. In the present article we also review the calcium handling literature and show that, unlike action potential prolongation, calcium handling is most severely impaired late in the progression of heart disease. In the final section of the article we present a hypothesis that links the early compensatory action potential prolongation to the eventual impairment of calcium handling, via chronically elevated intracellular calcium, and provide a model for the progression from compensated hypertrophy to heart failure.
Action potential prolongation in human cardiac failure and in animal models of cardiac failure
Action potential prolongation is a consistent finding in human heart failure and animal models of cardiac insufficiency. The evidence for action potential prolongation in w x heart failure has been reviewed in detail previously 10,11 . In 1970, Coltart and Meldrum reported that action potential duration was prolonged in septal tissue from a patient w x with hypertrophic cardiomyopathy 12 . Action potential duration was also shown to be prolonged in cardiac trabeculae from the hearts of patients with end-stage heart failure caused by either dilated cardiomyopathy and hypertrophic w x cardiomyopathy 13,14 and, more recently, in single cells isolated from hearts of patients with end stage heart failure caused by either dilated cardiomyopathy or ischaemic heart w x disease 15,16 . Prolongation of the cardiac action potential duration also occurs in a variety of animal models of cardiac hypertrophy, disease and failure. For example, action potential prolongation was shown in the hypertrophied cat right ventricle following pulmonary artery w x banding 17-20 . In the rat, action potentials were prolonged in association with hypertrophy induced by hyperw x w x tension in the Goldblatt 21-23 and SHR models 24,25 w x and following deoxycorticosterone acetate treatment 26 . Action potential prolongation is also associated with hyw x pertrophy secondary to left coronary artery ligation 27,28 , w x pulmonary artery ligation 29 , thoracic or abdominal aor-
Ž .
q Ž . Fig. 1 . A Action potentials, B the transient outward K current I to Ž . and C calcium transients in rat heart. Action potentials and I were to recorded from single right ventricular myocytes using the whole cell voltage clamp technique. Calcium transients were recorded from fura-2 loaded trabeculae from the right ventricle. The figure shows that action potential duration is prolonged 6-8 weeks post-myocardial infarction Ž . MI compared to sham control and that action potential prolongation is associated with a decrease in the density of I and an elevation in the x w x tic banding 30,31 , acromegaly 32 and catecholamine w x treatment 33 . Prolongation of action potential duration occurs following pulmonary artery constriction in the ferw x ret 34 , in Syrian hamsters with hereditary cardiac hyperw x trophy 35,36 , in guinea pigs following thoracic or abdomw x inal banding 37,38 , in rabbits with hypertrophy induced w x by perinephritis hypertension 39 and in dogs with pacing w x induced heart failure 40 . In our laboratory, we have used a rat model in which ligation of the left anterior descend-Ž . ing coronary artery induces a large ) 35% left ventricular infarction leading to the development of a compenw x satory right sided ventricular hypertrophy 41 , and we find that this right ventricular hypertrophy is also associated Ž . with action potential prolongation Fig. 1 . 
The mechanism of action potential prolongation
Action potential profiles depend on a delicate balance Ž between depolarising L-type calcium current, I , sodium w x 11 . In two studies, L-type calcium current has been w x reported to increase 38,42 . However, more commonly, the L-type calcium current is either unchanged w x w x 15,20,28,31,41,43-45 , or decreased 46-49 and therefore, appears unlikely to be responsible for the prolongation of action potential duration seen in these studies. w x I may be increased in the hypertrophied heart 38 NarCa Ž w x. although contradictory data has been published 50,51 and pressure overload can induce increases in NaCa exw x changer expression 52 , suggesting that this electrogenic exchanger may also contribute to action potential prolongation in some animal models. More importantly, the expression of NarCa exchanger is consistently found to Ž . increase in end-stage human heart failure Table 2 .
Altered background hyperpolarising currents could also impact on the action potential profile of hypertrophied and failing hearts, although the extent to which these currents contribute to action potential prolongation is unclear. Thus, in animal models of cardiac hypertrophy, the activity ofw x the Na ,K -ATPase is decreased 53-58 , along withw x altered Na ,K -ATPase isoform expression 59-63 . In human heart failure there is evidence for reduced concenŽ . tration of the Na ,K -ATPase oubain binding sites but w x no evidence for any subunit isoform switch 64-66 . One study to date has shown evidence for de-noÕo expression Ž of a background chloride current which would tend to
. w x counteract action potential prolongation 67 .
Potassium currents are the major repolarising currents active during the plateau of the action potential in myocytes isolated from a variety of model species and human hearts. Several groups have now measured K q currents in human heart failure and in animals models of cardiac hypertrophy and these data are summarised in mechanism underlying the reduced K q current density in cardiac hypertrophy. These studies show that compensated hypertrophy following MI in the rat is associated with a decrease in the transcription of Kv4.2 and Kv4.3, the probable molecular correlates of I in rat. The transcripto tion of some K q channel genes encoding I -like currents K Ž . Kv2.1, ERG is also decreased during hypertrophy in w x animals and human hearts 79 although the functional consequences of decreased transcription have not been identified. In contrast, we find that mRNA levels for genes encoding inward rectifiers, IRK1 and IRK2, are unchanged in the hypertrophied heart, despite electrophysiological w x evidence for decreased I in the same model 41 . These K1 q Ž findings suggest that decreased K current density and . action potential prolongation may be the result of reduced K q channel gene expression at both the transcriptional and post-transcriptional level. Interestingly, the fetal K q chanw x nel gene, Kv1.4 80,81 appears to be re-expressed in the w x q hypertrophied myocyte 41,82 suggesting that altered K channel gene expression represents yet another facet of the re-expression of fetal genes in cardiac hypertrophy.
The role of the sympathetic nerÕous system
The mechanism by which K q channel expression is Ž . reduced and action potential duration is increased in hypertrophy and failure is not clear. However, reflex activation of the sympathetic nervous system occurs immediately in response to an insult to pump function. Acute administration of a-adrenergic agonists is known to prow x long action potential duration 83-85 by a mechanism that q Ž w x involves inhibition of repolarising K currents I 86-88 , to w x w x. I 89,90 and I 91 without significant effects on I K K 1 C a w x 86,92-94 . Thus, while chronic activation of the sympathetic nervous system is associated with a reduction in the w x positive inotropic effects of a-agonists 95 , it seems plausible that a -adrenoreceptor stimulation following activa-1 tion of the sympathetic nervous system contributes to the initial action potential prolongation following acute alterations in loading of the myocardium.
The consequences of action potential prolongationeleÕated intracellular calcium and positiÕe inotropy: a compensatory response
It has long been recognised that action potential height andror duration is an important regulator of the amount of w x calcium released from intracellular storage sites 96-100 . Furthermore, interventions that induce a prolongation of the action potential, such as a-adrenoreceptor stimulation, increase the amplitude of the calcium transient in cardiac w x myocytes 86 . In rat cardiac trabeculae, we find that Ž . inhibition of the transient outward potassium current I to and prolongation of the action potential with 4-aminopyridine also enhances the amplitude of the calcium tran-Ž . sient Fig. 1 . Prolongation of simulated action potentials using the action potential clamp technique has shown unequivocally that prolonged depolarisation can directly w x increase the amplitude of the calcium transient 101 . The mechanism by which action potential duration influences the amount of calcium released during cardiac excitation probably involves the two key sarcolemmal proteins involved in calcium cycling, the L-type calcium channel and the NarCa exchanger, since the function of both these proteins is directly influenced by the membrane potential. Prolonged depolarisation during the plateau of extended action potentials enhances calcium entry via the L-type calcium channel and retards calcium extrusion via the NarCa exchanger, thereby loading the cell with calcium w x 101,102 .
Elevated calcium transients have also been recorded in animal models of moderate cardiac hypertrophy. Differences in systolic calcium that exist between hypertrophied and normal myocytes are abolished under voltage clamp conditions where the duration of depolarisation is norw x malised 103 , suggesting that action potential prolongation is responsible for the elevated systolic calcium seen in the hypertrophied myocyte. Since increases in the amplitude of the calcium transient are inotropic, it seems plausible that the reduction in K q channel expression and action potential prolongation represents and early compensatory response of the heart to an increased load, thereby increasing contractility.
Compensatory action potential prolongation is, however, potentially arrhythmogenic and as such this compensatory mechanism may predispose the heart to lethal arw x rhythmias 104 . In addition, in Section 4 we propose that Ž chronic elevation in intracellular calcium as a result of . action potential prolongation may potentiate mitogenic signalling cascades, leading to maladaptive gene expres-Ž . sion see below , over-riding any short term benefit and contributing to disease progression.
Calcium handling in hypertrophy and failure
Release and reuptake of intracellular calcium are essential for efficient contraction and relaxation of the heart. Intracellular calcium is released via ryanodine sensitive calcium channels located in the SR, in response to calcium entering during the plateau phase of the action potential. The two main pathways for calcium removal are the SR CaATPase, which resequesters calcium into the SR, and the sarcolemmal NaCa exchanger. The available data from animal models suggest that the calcium handling properties of hypertrophied myocytes are highly stage dependent. In moderate hypertrophy in animal models the expression of genes encoding calcium handling proteins is relatively w x normal 105-109 . Indeed, during compensated hypertrophy, we and others find that systolic calcium is actually Despite continued action potential prolongation howw x ever, systolic calcium is severely reduced 15 , the calcium w x 2q transient is significantly prolonged 13-15,112 and Ca w x uptake activity may be reduced 113-115 in more advanced stages of hypertrophy in animal models and in end-stage heart failure in humans. In animal models of severe hypertrophy, these events correlate with the finding that the expression of genes encoding calcium handling w x proteins is markedly reduced 105-109 . Although the mechanisms underlying altered calcium handling in endstage human heart failure are not entirely clear, and there is currently controversy concerning the extent to which RNA levels are predictive of protein levels, a number of studies have demonstrated altered expression of genes Ž encoding calcium handling proteins including SR CaAT-Ž . Ž . Pase SERCA2 , ryanodine receptor RYR2 , NaCa ex-. changer and phospholamban genes , and these are summarised in Table 2 .
Unlike the changes that lead to action potential prolon-Ž . gation see Sections 2.1 and 2.2 therefore, impaired calcium handling appears to be a relatively late event in the progression toward failure. In contrast to altered K q channel expression, it appears that changes in calcium handling may be maladaptive rather than compensatory, and may lead to severely impaired systolic and diastolic cardiac w x function, heralding the onset of failure 105 .
At present the events leading to the late changes in calcium handling are poorly understood. However, chronic activation of compensatory mechanisms including action potential prolongation may trigger these late events. In the following sections we outline a hypothesis which describes a potential role for action potential prolongation, and the associated elevation in the levels of intracellular calcium, in the regulation of calcium handling gene expression.
4. The contribution of action potential prolongation and elevated intracellular calcium to altered gene expression and the progression of heart failure: a hypothesis
The potential role for prolonged action potential duration in the progression of heart failure is outlined in Fig. 2 . Decreased pump function as a result of myocardial infarction, hypertension or genetic abnormalities triggers a compensatory response which involves altered K q channel gene expression. Prolonged action potential depolarisation results in elevated intracellular calcium which may acutely support the compromised heart. Elevated intracellular calcium however, may also potentiate mitogenic signalling cascades, leading to maladaptive gene expression, which may initially blunt the compensatory response and ultimately depress cardiac function, accelerating the progression toward failure.
Membrane depolarisation and calcium entry are important determinants of gene expression in a number of w x excitable cells 127-132 . Similarly, and consistent with the hypothesis, gene expression in cardiac myocytes has also been shown to be dependent on calcium. For example, NE treatment of cultured neonatal myocytes induces a decreased expression of SERCA2 and the decrease in SERCA2 can be abolished in contractile arrested and w x verapamil treated myocytes 133 , implying that excitation-contraction coupling and calcium current through . such as decreased SR Ca ATPase expression , which blunt the compensatory response and ultimately contribute to the progression from compensatory hypertrophy to cardiac failure. -----shows the compensatory response which supports cardiac output, shows the maladaptation which may contribute to failure. the L-type calcium channel are important in the phenotypic response to a-adrenergic agonists. Furthermore, the induction of the immediate early genes c-fos and Egr-1 by ET and ANGII in cultured adult cardiocytes is inhibited by the w x calcium antagonist, nisoldipine 134 and in neonatal myocytes, induction of the muscle specific genes MLC-2, a-actin and troponin I by ET could be mimicked by the w x calcium ionophore, ionomycin 135 .
Given the potential role for altered gene expression in the pathogenesis of heart failure, the signalling cascades that lead to altered gene expression in heart failure have been the subject of intense research over the last decade. In-vitro and in-vivo studies have shown that altered gene expression can be induced by a number of stimuli including a-and b-adrenergic agonists, angiotensin II, endothelin, growth factors and mechanical activity. 
Implications for treatment
Morbidity and mortality in heart failure remain unacceptably high. Despite recent advances in medical treatment, heart failure remains a highly lethal disease. As we have argued, action potential prolongation and the associated elevation in systolic calcium may contribute to maladaptive gene expression and the progression toward cardiac failure, as well as to the high incidence of sudden cardiac death in patients with heart failure. Accordingly, it is possible to predict that agents that further prolong action Ž . potential duration such as class III anti-arrhythmic agents Ž or increase calcium availability such as positive inotropic . agents would be detrimental in the setting of cardiac hypertrophy and failure. Indeed, clinical practise supports this contention since the class III anti-arrhythmic agent, w x w x d-sotalol 159 and positive inotropic agents 160,161 have generally been found to be detrimental in this patient group. On the contrary, agents that normalise action potential duration or reduce the availability of calcium may be beneficial. Reductions in the availability of calcium may explain some recent findings showing the long acting w x calcium antagonist, amlodipine 162 , and the T-type calw x cium channel antagonist, mibefridil 163 , are beneficial in human heart failure and in animal models of cardiac hypertrophy.
Since action potential prolongation in heart failure involves a reduction the net outward repolarising K q current, a novel approach to the treatment of heart failure would be to normalise K q channel gene expression. Conw x ceivably, this could be achieved by gene transfer 164 or pharmacologically. With regard to the latter we and others have recently shown that thyroid hormone is capable of increasing K q channel expression at the transcriptional w x level in rat ventricular myocytes 81,165 . The possibility exists therefore, that agents with thyroid hormone-like properties may find a role in the treatment of heart failure.
Future directions
In order to determine the role of action potential prolongation in the pathogenesis of cardiac failure we have created transgenic mice which over-express an N-terminus fragment of the rat Kv4.2 gene in a cardiac restricted w x manner 166 . Over-expression of this fragment in-vitro abolishes functional expression of full length Kv4.2 in heterologous expression systems. We hypothesised that in mice this construct should suppress functional expression of I , leading to action potential prolongation in the to absence of any other trophic stimuli. Preliminary data suggest that these mice develop frank congestive heart w x failure resulting in death at 2-3 months of age 166 . An understanding of the mechanism by which dominant negative inhibition of K q channels in the mouse heart leads to failure may help clarify the role of K q channel down-regulation in the pathogenesis of heart disease.
Since action potential prolongation and the associated increase in intracellular calcium may play a central role in the pathogenesis and progression of heart failure, it is of particular interest to note that membrane depolarisation and intracellular calcium may also be capable of regulating A number of recent studies have implicated myocyte loss as an important factor in the progressive mechanical w x dysfunction that leads ultimately to cardiac failure 5 . While cell death can occur by necrosis or apoptosis, the latter appears predominant in the dog model of chronic w x pacing induced heart failure 6 , in dogs with heart failure w x induced by multiple intracoronary microemboli 7 and in w x rats following experimental left ventricular infarction 8,9 . The factors that trigger apoptosis in the hypertrophied myocardium are unknown. However, studies using noncardiac cells have identified intracellular calcium as an w x important regulator of programmed cell death 168,169 . In w x w x cardiac myocytes, stretch 170 and angiotensin II 171 have been shown capable of inducing apoptosis and, consistent with an important role for calcium, apoptosis induced by angiotensin II in adult rat ventricular myocytes can be inhibited by the calcium chelator BAPTArAM and w x mimicked by the calcium ionophore, A23187 171 . Further studies to explore the possible link between increases Ž in intracellular calcium secondary to action potential pro-. longation and apoptosis in the overloaded heart are clearly warranted.
Summary
Altered K q channel expression and action potential prolongation is a common finding in heart disease. Previous studies have focused on the arrhythmogenic consequences of these alterations. However, given the connection between action potential profile, intracellular calcium concentration and myocyte gene expression, it seems plausible that altered K q channel expression and action potential prolongation may also play a more insidious role in disease progression. 
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